Permanent cure for male-pattern baldness.Cosmo has released its Phase III trial results

[Sam480]

 

[Sam480]

 

[Sam480]

https://www.cosmopharma.com/news/cosmo-announces-breakthrough-phase-iii-topline-results-from-scalp-1-and-scalp-2-for-clascoterone-5-solution-in-male-hair-loss-showing-up-to-539-relative-improvement-in-target-area-hair-count-vs-place

Cosmo announces breakthrough Phase III Topline results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in male hair loss, showing up to 539% relative improvement in Target-Area Hair Count vs placebo; US and EU submissions are underway

Ad hoc announcement pursuant to Art. 53 LR

• 1,465 patients were randomized into the two identical-in-design clinical studies Scalp 1 (NCT05910450) and Scalp 2 (NCT05914805)
• Both studies reached statistically significant endpoints in TAHC (Target-Area Hair Count), with one reaching 539% relative improvement to placebo and the second study reaching 168% relative improvement to placebo
• Positive safety profile demonstrated across both studies
• Positive safety profile demonstrated across both studie Largest Phase III program ever conducted for a Topical Treatment for Male Androgenetic Alopecia (AGA)
• First novel mechanism of action and first potential innovation in over 30 years in male hair loss
• Preparations are underway for parallel regulatory submissions in the United States and Europe